CardioMEMS’ Heart Failure Monitor Foiled At Panel By FDA Inspection Findings Of Study Bias

The firm’s PMA hopes are in question after recommendations made by company nurses to investigators in the CHAMPION trial, uncovered during FDA clinical-site inspections, dominated last week’s advisory panel meeting. The panel voted 6-4 that the benefits of the device do not outweigh its risks.

An FDA panel meeting last week on CardioMEMS Inc.’s PMA for its Champion implantable heart failure monitor was dominated not by the firm’s clinical data but by findings from FDA’s pre-market clinical-site inspections pointing to bias in that data.

The result: CardioMEMS appears to be facing an uphill battle at best for approval. That is a disappointing surprise not only for Atlanta-based CardioMEMS, but also for St. Jude Medical,...

More from United States

More from North America